Immunomodulation by targeted anticancer agents

Giulia Petroni; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1016/j.ccell.2020.11.009

Immunomodulation by targeted anticancer agents

Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journal › Review article › peer-review

142 Scopus citations

Abstract

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

Original language	English
Pages (from-to)	310-345
Number of pages	36
Journal	Cancer Cell
Volume	39
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2020.11.009
State	Published - Mar 8 2021
Externally published	Yes

Keywords

BRAF
CD8 cytotoxic T lymphocytes
CDK4/CDK6
CGAS signaling
DNA damage response
EGFR
KRAS
T cells
TGF-β
immune checkpoint blockers
immunogenic cell death
Humans
Antineoplastic Agents/immunology
Disease Progression
Animals
Neoplasms/immunology
Immunomodulation/immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2020.11.009

Cite this

@article{30ff1bc3beda49538f7918da8e85bd3c,

title = "Immunomodulation by targeted anticancer agents",

abstract = "At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.",

keywords = "BRAF, CD8 cytotoxic T lymphocytes, CDK4/CDK6, CGAS signaling, DNA damage response, EGFR, KRAS, T cells, TGF-β, immune checkpoint blockers, immunogenic cell death, Humans, Antineoplastic Agents/immunology, Disease Progression, Animals, Neoplasms/immunology, Immunomodulation/immunology",

author = "Giulia Petroni and Aitziber Buqu{\'e} and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

year = "2021",

month = mar,

day = "8",

doi = "10.1016/j.ccell.2020.11.009",

language = "English",

volume = "39",

pages = "310--345",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Immunomodulation by targeted anticancer agents

AU - Petroni, Giulia

AU - Buqué, Aitziber

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2021/3/8

Y1 - 2021/3/8

N2 - At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

AB - At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

KW - BRAF

KW - CD8 cytotoxic T lymphocytes

KW - CDK4/CDK6

KW - CGAS signaling

KW - DNA damage response

KW - EGFR

KW - KRAS

KW - T cells

KW - TGF-β

KW - immune checkpoint blockers

KW - immunogenic cell death

KW - Humans

KW - Antineoplastic Agents/immunology

KW - Disease Progression

KW - Animals

KW - Neoplasms/immunology

KW - Immunomodulation/immunology

UR - http://www.scopus.com/inward/record.url?scp=85099254821&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.11.009

DO - 10.1016/j.ccell.2020.11.009

M3 - Review article

C2 - 33338426

AN - SCOPUS:85099254821

SN - 1535-6108

VL - 39

SP - 310

EP - 345

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -

Immunomodulation by targeted anticancer agents

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this